-
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS, 2011: A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge[J]. J Virol, 85, 12201-12215. doi: 10.1128/JVI.06048-11
-
Chen IY, Moriyama M, Chang MF, Ichinohe T, 2019: Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome[J]. Front Microbiol, 10, 50-. doi: 10.3389/fmicb.2019.00050
-
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L, 2020: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, , -. doi: 10.1016/S0140-6736(20)30211-7
-
Clay C, Donart N, Fomukong N, Knight JB, Lei W, Price L, Hahn F, Van Westrienen J, Harrod KS, 2012: Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge[J]. J Virol, 86, 4234-4244. doi: 10.1128/JVI.06791-11
-
Fink SL, Cookson BT, 2005: Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells[J]. Infect Immun, 73, 1907-1916. doi: 10.1128/IAI.73.4.1907-1916.2005
-
Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Muench MO, Simmons G, Hofmann H, Kuri T, Weber F, Eichler J, Drosten C, Pöhlmann S, 2010: Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63[J]. J Virol, 84, 1198-1205. doi: 10.1128/JVI.01248-09
-
Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS, 2005: Multiple organ infection and the pathogenesis of SARS[J]. J Exp Med, 202, 415-424. doi: 10.1084/jem.20050828
-
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, 2020: Clinical characteristics of 2019 novel coronavirus infection in China[J]. MedRxiv, , -. doi: 10.1101/2020.02.06.20020974
-
Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y, 2008: Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry[J]. Proc Natl Acad Sci U S A, 105, 7809-7814. doi: 10.1073/pnas.0711241105
-
Halstead SB, O'Rourke EJ, 1977: Antibody-enhanced dengue virus infection in primate leukocytes[J]. Nature, 265, 739-741. doi: 10.1038/265739a0
-
Haslwanter D, Blaas D, Heinz FX, Stiasny K, 2017: A novel mechanism of antibody-mediated enhancement of flavivirus infection[J]. PLoS Pathog, 13, e1006643-. doi: 10.1371/journal.ppat.1006643
-
Horiuchi T, Tsukamoto H, 2016: Complement-targeted therapy: development of C5- and C5a-targeted inhibition[J]. Inflamm Regen, 36, 11-. doi: 10.1186/s41232-016-0013-6
-
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B, 2020: Clinical features of patients infected with 2019 novel coronavirus in Wuhan[J]. Lancet China, , -. doi: 10.1016/S0140-6736(20)30183-5
-
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM, 2005: Angiotensin-converting enzyme 2 protects from severe acute lung failure[J]. Nature, 436, 112-116. doi: 10.1038/nature03712
-
Imai Y, Kuba K, Penninger JM, 2008: The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice[J]. Exp Physiol, 93, 543-548. doi: 10.1113/expphysiol.2007.040048
-
Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB Jr, 2009: Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia[J]. Am J Physiol Lung Cell Mol Physiol, 297, L84-L96. doi: 10.1152/ajplung.00071.2009
-
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM, 2005: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury[J]. Nat Med, 11, 875-879. doi: 10.1038/nm1267
-
Kuba K, Imai Y, Penninger JM, 2006: Angiotensin-converting enzyme 2 in lung diseases[J]. Curr Opin Pharmacol, 6, 271-276. doi: 10.1016/j.coph.2006.03.001
-
Kurlander RJ, Hall J, 1986: Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice[J]. J Clin Invest, 77, 2010-2018. doi: 10.1172/JCI112530
-
Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ, 2005: Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)[J]. J Biol Chem, 280, 30113-30119. doi: 10.1074/jbc.M505111200
-
Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z, 2019: Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J]. JCI Insight, , -. doi: 10.1172/jci.insight.123158
-
Nimmerjahn F, Ravetch JV, 2008a: Analyzing antibody-Fc-receptor interactions[J]. Methods Mol Biol, 415, 151-162.
-
Nimmerjahn F, Ravetch JV, 2008b: Anti-inflammatory actions of intravenous immunoglobulin[J]. Annu Rev Immunol, 26, 513-533. doi: 10.1146/annurev.immunol.26.021607.090232
-
Nimmerjahn F, Ravetch JV, 2008c: Fcgamma receptors as regulators of immune responses[J]. Nat Rev Immunol, 8, 34-47. doi: 10.1038/nri2206
-
Ochiai H, Kurokawa M, Matsui S, Yamamoto T, Kuroki Y, Kishimoto C, Shiraki K, 1992: Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody[J]. J Med Virol, 36, 217-221. doi: 10.1002/jmv.1890360312
-
Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY, HKU/UCH SARS Study Group (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767–1772
-
Takada A, Kawaoka Y, 2003: Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications[J]. Rev Med Virol, 13, 387-398. doi: 10.1002/rmv.405
-
Takada A, Feldmann H, Ksiazek TG, Kawaoka Y, 2003: Antibody-dependent enhancement of Ebola virus infection[J]. J Virol, 77, 7539-7544. doi: 10.1128/JVI.77.13.7539-7544.2003
-
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB, 2012: Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J]. PLoS ONE, 7, e35421-. doi: 10.1371/journal.pone.0035421
-
van Mirre E, van Royen A, Hack CE, 2004: IVIg-mediated amelioration of murine ITP via FcgammaRIIb is not necessarily independent of SHIP-1 and SHP-1 activity[J]. Blood, 103, 1973-. doi: 10.1182/blood-2003-11-3933
-
Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S, 2007: Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization[J]. Immunology, 121, 392-404. doi: 10.1111/j.1365-2567.2007.02588.x
-
Wang S, Guo F, Liu K, Wang H, Rao S, Yang P, Jiang C, 2008: Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2[J]. Virus Res, 136, 8-15. doi: 10.1016/j.virusres.2008.03.004
-
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ, 2004: Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol, 136, 95-103. doi: 10.1111/j.1365-2249.2004.02415.x
-
Yang M (2020) Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN. https://doi.org/10.2139/ssrn.3527420
-
Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, Ba L, Li W, Farzan M, Chen Z, Yuen KY, Ho D, 2006: Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals[J]. J Med Virol, 78, 1-8. doi: 10.1002/jmv.20499
-
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zou W, 2020: Single-Cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV[J]. BioRxiv, , -. doi: 10.1101/2020.01.26.919985
-
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL, 2020: A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, , -. doi: 10.1038/s41586-020-2012-7